UBS raised the firm’s price target on PTC Therapeutics (PTCT) to $71 from $47 and keeps a Buy rating on the shares. PTC Therapeutics on Monday announced a global licensing and collaboration agreement ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
News Medical on MSN13h
Heart medication may slow the progression of Huntington's diseaseResearch indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...
A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the fatal illness. Huntington’s is an inherited condition that is caused by a ...
GlobalData on MSN14h
Patient data understanding must be a priority in trials, say expert panelSpeaking at the 11th Annual Clinical Trials in Oncology conference in Munich, a panel of experts urged trial designers to be ...
Novartis, Gilead, Roche and Takeda commit to new partners in a spate of mid-sized collaborations this week. Meanwhile, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback